MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
TMBR - Timber Pharmaceuticals Inc
$2.23
0.59(35.98%)8:53:47 PM 2/24/2021
Timber Pharmaceuticals LLC, a clinical-stage medical dermatology company, focuses on the development and commercialization of pharmaceuticals for treatment of orphan dermatologic diseases. The company was founded in 2019 and is based in Woodcliff Lake, New Jersey.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    01/25/2021TMBR
    Timber Pharmaceuticals Appoints Alan Mendelsohn, M.D., as Chief Medical Officer

    Dr. Mendelsohn has 20+ Years’ Experience in Clinical Development and Medical Affairs WOODCLIFF LAKE, NJ, Jan. 25, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the appointment of Alan Mendelsohn, M.D., as Chief Medical Officer. Dr. Mendelsohn assumes the roles and respon...

    01/12/2021TMBR
    Timber Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis

    Timber Expects to Submit Investigational New Drug (IND) Application to the FDA in 2022WOODCLIFF LAKE, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire \-- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TMB-003, the compan...

    12/15/2020TMBR
    Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Lead Asset TMB-001

    \- Formal notice confirms intent to grant patent for pharmaceutical isotretinoin composition -WOODCLIFF LAKE, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire \-- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has received a formal notice of allowance from the U.S. Patent and Trademark Office (USPTO)...

    12/10/2020TMBR
    Timber Pharmaceuticals Hosts Business Update Conference Call

    Call to be held on Thursday, December 17th at 11:00am ESTWOODCLIFF LAKE, N.J., Dec. 10, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire \-- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it will hold a business update conference call for investors and shareholders. The call will be hosted by Timber’s Chief Executive ...

    12/8/2020TMBR
    Timber Pharmaceuticals to Present at the 13th Annual LD Micro Main Event Conference

    Presentation on Tuesday December 15th  at 10:40am EST LOS ANGELES, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire \-- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announcedthat it will be presenting at the 13th annual LD Micro Main Event investor conference on Tuesday, December 15, 2020 at 10:40 AM EST / 7:40 AM PS...

    11/20/2020TMBR
    Timber Pharmaceuticals Signs Waiver Agreement with Warrant Holders

    WOODCLIFF LAKE, NJ, Nov. 20, 2020 (GLOBE NEWSWIRE) -- NewMediaWire \-- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has signed waiver agreements with certain of its existing institutional investors.  Effective as of November 19, 2020 (the “Effective Date”), Timber entered into waiver agreements (the “Waiv...